A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer (CC1C)

Cancer Advances

Status and phase

Terminated

Phase 2

Conditions

Colorectal Cancer

Treatments

Biological: G17DT

Study type

Interventional

Funder types

Industry

Identifiers

NCT02228785

CC1C

Details and patient eligibility

About

This study was designed to investigate the safety and tolerance of three doses (100µg, 200µg, 500µg) of G17DT for the treatment of patients with colorectal cancer.

Enrollment

5 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged 18 years or over with histologically verified adenocarcinoma of colon or rectum.
Recurrent of metastatic disease not amenable to curative surgery and/or radiotherapy.
Life expectancy greater than 3 months.
Karnofsky Index Score greater than or equal to 50%.
Written informed consent obtained.

Exclusion criteria

Neoplastic lesions other than colorectal cancer (except treated basal cell carcinoma of the skin or cancer of the uterine cervix, through Stage I.
Acute intercurrent illness.
Patient considered to be a medical risk because of non-malignant systemic disease or grossly abnormal laboratory results.
Patients who had received any other anticancer therapy within 3 months.
Factor liable to alter the serum gastrin concentration or affect intra-gastric acidity, for instance concomitant therapy with H2 receptor antagonist drugs, proton pump inhibitors, or previous gastric surgery.
Patients immunologically compromised including those on corticosteroid therapy.
Women of child-bearing age.
Positive immediate hypersensitivity reaction to skin testing with study medication.
Patients unable to complete the diary book
Haematogical Status Haemoglobin count less than 10g/dL White Blood Cell count less than 4.0 x 10^9/L Platelet count less than 100 x 10^9/L